D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 105 Citations 70,676 454 World Ranking 3890 National Ranking 136

Overview

What is he best known for?

The fields of study Martin J. van den Bent is best known for:

  • Cancer
  • Chemotherapy
  • Gene

His study deals with a combination of Internal medicine and Psychiatry. He undertakes multidisciplinary investigations into Psychiatry and Internal medicine in his work. His work blends Oncology and Gastroenterology studies together. In his papers, Martin J. van den Bent integrates diverse fields, such as Gastroenterology and Oncology. In his papers, he integrates diverse fields, such as Cancer research and Cancer. Martin J. van den Bent conducted interdisciplinary study in his works that combined Cancer and Radiation therapy. He integrates Radiation therapy with Astrocytoma in his study. His Astrocytoma study frequently draws parallels with other fields, such as Oligodendroglial Tumor. His Oligodendroglial Tumor study frequently draws connections between adjacent fields such as Oligodendroglioma.

His most cited work include:

  • Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma (15818 citations)
  • Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (5912 citations)
  • Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group (2906 citations)

What are the main themes of his work throughout his whole career to date

His Internal medicine study often links to related topics such as Randomized controlled trial. With his scientific publications, his incorporates both Oncology and Cancer. His Cancer research study frequently draws connections between related disciplines such as Glioblastoma. Glioma is closely attributed to Genetics in his work. Genetics is frequently linked to Glioma in his study. Martin J. van den Bent performs multidisciplinary studies into Chemotherapy and Surgery in his work. He performs integrative Surgery and Chemotherapy research in his work. His work blends Temozolomide and Radiation therapy studies together. He performs multidisciplinary study on Radiation therapy and Temozolomide in his works.

Martin J. van den Bent most often published in these fields:

  • Internal medicine (80.58%)
  • Oncology (66.67%)
  • Cancer research (55.99%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Roger Stupp;Warren P. Mason;Martin J. van den Bent;Michael Weller.
The New England Journal of Medicine (2005)

19131 Citations

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Roger Stupp;Monika E. Hegi;Warren P. Mason;Martin J. van den Bent.
Lancet Oncology (2009)

9394 Citations

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

Patrick Y. Wen;David R. Macdonald;David A. Reardon;Timothy F. Cloughesy.
Journal of Clinical Oncology (2010)

3368 Citations

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

Dieta Brandsma;Lukas Stalpers;Walter Taal;Peter Sminia.
Lancet Oncology (2008)

1287 Citations

Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma

Francesco Pignatti;Martin van den Bent;Desmond Curran;Channa Debruyne.
Journal of Clinical Oncology (2002)

1109 Citations

Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

Martin J. van den Bent;Alba A. Brandes;Martin J.B. Taphoorn;Johan M. Kros.
Journal of Clinical Oncology (2013)

1101 Citations

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Roger Stupp;Roger Stupp;Monika E Hegi;Thierry Gorlia;Sara C Erridge.
Lancet Oncology (2014)

976 Citations

Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial

Martin J. van den Bent;Antoine F. Carpentier;Alba A. Brandes;Marc Sanson.
Journal of Clinical Oncology (2006)

955 Citations

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

Walter Taal;Hendrika M Oosterkamp;Annemiek M E Walenkamp;Hendrikus J Dubbink.
Lancet Oncology (2014)

791 Citations

European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas

Michael Weller;Martin van den Bent;Jörg C Tonn;Roger Stupp.
Lancet Oncology (2017)

762 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Martin J. van den Bent

Michael Weller

Michael Weller

University of Zurich

Publications: 313

Wolfgang Wick

Wolfgang Wick

German Cancer Research Center

Publications: 300

Patrick Y. Wen

Patrick Y. Wen

Harvard University

Publications: 273

David A. Reardon

David A. Reardon

Harvard University

Publications: 203

Timothy F. Cloughesy

Timothy F. Cloughesy

University of California, Los Angeles

Publications: 200

Andreas von Deimling

Andreas von Deimling

Heidelberg University

Publications: 164

Mark R. Gilbert

Mark R. Gilbert

National Institutes of Health

Publications: 156

Tracy T. Batchelor

Tracy T. Batchelor

Brigham and Women's Hospital

Publications: 149

Jeremy N. Rich

Jeremy N. Rich

University of Pittsburgh

Publications: 139

Susan M. Chang

Susan M. Chang

University of California, San Francisco

Publications: 139

Roger Stupp

Roger Stupp

Northwestern University

Publications: 133

Kenneth D. Aldape

Kenneth D. Aldape

Princess Margaret Cancer Centre

Publications: 132

Tao Jiang

Tao Jiang

Capital Medical University

Publications: 123

Guido Reifenberger

Guido Reifenberger

Heinrich Heine University Düsseldorf

Publications: 120

Lisa M. DeAngelis

Lisa M. DeAngelis

Memorial Sloan Kettering Cancer Center

Publications: 119

Pieter Wesseling

Pieter Wesseling

University of Amsterdam

Publications: 117

Trending Scientists

Marco Chiani

Marco Chiani

University of Bologna

Daniel James Winarski

Daniel James Winarski

IBM (United States)

Chaobo Huang

Chaobo Huang

Nanjing Forestry University

Luis Martín-Moreno

Luis Martín-Moreno

University of Zaragoza

Xiaoxing Xi

Xiaoxing Xi

Temple University

Csaba Koncz

Csaba Koncz

Max Planck Society

Werner M. Kaiser

Werner M. Kaiser

University of Würzburg

Timothy D. Mastro

Timothy D. Mastro

Family Health International 360

Dennis W. Trent

Dennis W. Trent

The University of Texas Medical Branch at Galveston

Steven C. Hardiman

Steven C. Hardiman

Met Office

Robert H. LaMotte

Robert H. LaMotte

Yale University

Conrad E. Johanson

Conrad E. Johanson

Brown University

Michael R. Lowe

Michael R. Lowe

Drexel University

Giampaolo Perna

Giampaolo Perna

Humanitas University

Harvey M. Golomb

Harvey M. Golomb

University of Chicago

Katepalli R. Sreenivasan

Katepalli R. Sreenivasan

New York University

Something went wrong. Please try again later.